225 related articles for article (PubMed ID: 30184505)
1. Structural Basis of Pan-Ebolavirus Neutralization by an Antibody Targeting the Glycoprotein Fusion Loop.
Murin CD; Bruhn JF; Bornholdt ZA; Copps J; Stanfield R; Ward AB
Cell Rep; 2018 Sep; 24(10):2723-2732.e4. PubMed ID: 30184505
[TBL] [Abstract][Full Text] [Related]
2. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO
mBio; 2018 Sep; 9(5):. PubMed ID: 30206174
[TBL] [Abstract][Full Text] [Related]
4. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
Holtsberg FW; Shulenin S; Vu H; Howell KA; Patel SJ; Gunn B; Karim M; Lai JR; Frei JC; Nyakatura EK; Zeitlin L; Douglas R; Fusco ML; Froude JW; Saphire EO; Herbert AS; Wirchnianski AS; Lear-Rooney CM; Alter G; Dye JM; Glass PJ; Warfield KL; Aman MJ
J Virol; 2016 Jan; 90(1):266-78. PubMed ID: 26468533
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
[TBL] [Abstract][Full Text] [Related]
6. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K
Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of broad ebolavirus neutralization by a human survivor antibody.
West BR; Wec AZ; Moyer CL; Fusco ML; Ilinykh PA; Huang K; Wirchnianski AS; James RM; Herbert AS; Hui S; Goodwin E; Howell KA; Kailasan S; Aman MJ; Walker LM; Dye JM; Bukreyev A; Chandran K; Saphire EO
Nat Struct Mol Biol; 2019 Mar; 26(3):204-212. PubMed ID: 30833785
[TBL] [Abstract][Full Text] [Related]
9. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
Front Immunol; 2021; 12():706757. PubMed ID: 34335620
[TBL] [Abstract][Full Text] [Related]
10. A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.
Bornholdt ZA; Herbert AS; Mire CE; He S; Cross RW; Wec AZ; Abelson DM; Geisbert JB; James RM; Rahim MN; Zhu W; Borisevich V; Banadyga L; Gunn BM; Agans KN; Wirchnianski AS; Goodwin E; Tierney K; Shestowsky WS; Bohorov O; Bohorova N; Velasco J; Ailor E; Kim D; Pauly MH; Whaley KJ; Alter G; Walker LM; Chandran K; Zeitlin L; Qiu X; Geisbert TW; Dye JM
Cell Host Microbe; 2019 Jan; 25(1):49-58.e5. PubMed ID: 30629918
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies.
Ilinykh PA; Shen X; Flyak AI; Kuzmina N; Ksiazek TG; Crowe JE; Bukreyev A
J Virol; 2016 Apr; 90(8):3890-3901. PubMed ID: 26819310
[TBL] [Abstract][Full Text] [Related]
12. Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40.
Yu DS; Weng TH; Shen L; Wu XX; Hu CY; Wang FXC; Wu ZG; Wu HB; Wu NP; Li LJ; Yao H
Cell Physiol Biochem; 2018; 50(3):1055-1067. PubMed ID: 30355918
[TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.
Nyakatura EK; Zak SE; Wec AZ; Hofmann D; Shulenin S; Bakken RR; Aman MJ; Chandran K; Dye JM; Lai JR
J Biol Chem; 2018 Apr; 293(16):6201-6211. PubMed ID: 29500195
[TBL] [Abstract][Full Text] [Related]
14. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.
Flyak AI; Kuzmina N; Murin CD; Bryan C; Davidson E; Gilchuk P; Gulka CP; Ilinykh PA; Shen X; Huang K; Ramanathan P; Turner H; Fusco ML; Lampley R; Kose N; King H; Sapparapu G; Doranz BJ; Ksiazek TG; Wright DW; Saphire EO; Ward AB; Bukreyev A; Crowe JE
Nat Microbiol; 2018 Jun; 3(6):670-677. PubMed ID: 29736037
[TBL] [Abstract][Full Text] [Related]
15. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.
Murin CD; Gilchuk P; Crowe JE; Ward AB
Front Immunol; 2021; 12():808047. PubMed ID: 35082794
[TBL] [Abstract][Full Text] [Related]
16. Pan-ebolavirus protective therapy by two multifunctional human antibodies.
Gilchuk P; Murin CD; Cross RW; Ilinykh PA; Huang K; Kuzmina N; Borisevich V; Agans KN; Geisbert JB; Zost SJ; Nargi RS; Sutton RE; Suryadevara N; Bombardi RG; Carnahan RH; Bukreyev A; Geisbert TW; Ward AB; Crowe JE
Cell; 2021 Oct; 184(22):5593-5607.e18. PubMed ID: 34715022
[TBL] [Abstract][Full Text] [Related]
17. Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease.
Luczkowiak J; Lasala F; Mora-Rillo M; Arribas JR; Delgado R
J Infect Dis; 2018 Nov; 218(suppl_5):S574-S581. PubMed ID: 29939289
[TBL] [Abstract][Full Text] [Related]
18. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA
Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755
[TBL] [Abstract][Full Text] [Related]
19. Structural Characterization of Pan-Ebolavirus Antibody 6D6 Targeting the Fusion Peptide of the Surface Glycoprotein.
Milligan JC; Parekh DV; Fuller KM; Igarashi M; Takada A; Saphire EO
J Infect Dis; 2019 Jan; 219(3):415-419. PubMed ID: 30203042
[TBL] [Abstract][Full Text] [Related]
20. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
